INTRODUCTION
============

Age-related macular degeneration (AMD) is the leading cause of irreversible and severe visual loss in subjects aged 50 years and above in developed countries.[@b1-jovr-3-95] Although the neovascular form of AMD represents only 10% of the disease, it is responsible for 90% of severe visual loss due to AMD.[@b2-jovr-3-95] Attempts made to prevent visual loss by targeting the neovascular lesion, include thermal laser photocoagulation[@b3-jovr-3-95][@b4-jovr-3-95] and photodynamic therapy (PDT).[@b5-jovr-3-95][@b6-jovr-3-95] Laser photocoagulation results in immediate destruction of the central macula and loss of vision in subfoveal and juxtafoveal choroidal neovascularization(CNV) lesions. PDT selectively occludes neovascular tissue but has not been shown to improve vision in patients with CNV.[@b7-jovr-3-95]--[@b9-jovr-3-95]

The vascular endothelial growth factor (VEGF) has been implicated as the major angiogenic stimulus for neovascularization in AMD, accordingly, anti-VEGF agents have recently been used to treat CNV secondary to AMD.[@b10-jovr-3-95]--[@b15-jovr-3-95] Bevacizumab, a full-length, humanized monoclonal anti-VEGF antibody has been successfully used for off-label treatment of neovascular AMD and CNV due to high myopia.[@b16-jovr-3-95]--[@b32-jovr-3-95]

Other agents such as triamcinolone acetonide have been tried with short-term success. Besides its anti-inflammatory effects, triamcinolone acetonide causes down-regulation of VEGF.[@b33-jovr-3-95] The combination of PDT and triamcinolone, has also been reported to be effecttive. [@b34-jovr-3-95]--[@b36-jovr-3-95] One case series has demonstrated successful triple therapy with PDT, bevacizumab and dexamethasone for exudative AMD.[@b37-jovr-3-95]

To our knowledge, no clinical trial has been performed to assess whether triamcinolone acetonide has an additive effect with bevacizumab. In the current study we compared the effect of intravitreal bevacizumab (IVB) with that of the combination of bevacizumab and triamcinolone (IVB/IVT) on subfoveal and juxtafoveal neovascular AMD.

METHODS
=======

This prospective, randomized, double-masked, two-center clinical trial was conducted from Dec. 2005 to April 2006. Subjects aged 50 years or older who had subfoveal or juxtafoveal CNV secondary to AMD with best-corrected visual acuity (BCVA) of 20/40 or less in the better eye and BCVA of 20/800-20/40 in the fellow eye were enrolled. All angiographic subtypes of AMD were included. To be eligible for inclusion inclusion, total lesion size (including hemorrhage, scar, atrophy and neovascularization) was limited to 12 disc areas (DA) with at least 50% of the lesion consisting of active CNV and less than 50% being occupied by subretinal hemorrhage. Using balanced block randomization, subjects were randomly assigned to receive either 1.25 mg intravitreal bevacizumab (IVB group) or a combination of 1.25 mg bevacizumab and 2mg intravitreal triamcinolone acetonide(IVB/IVT group). Eligible patients provided written informed consent. The study protocol was approved by the institutional review boards and ethics committees of the participating centers.

Intravitreal injections were performed using a standard protocol as follows: following topical anesthesia and scrubbing the lids and eyelashes using povidone-iodine 10%; the eyelids were retracted using a sterile speculum and povidone-iodine 5% drops were applied over the ocular surface. Using a \#30-gauge needle on an insulin syringe, 0.05 ml (1.25 mg) bevacizumab(Avastin, Genentech Inc., San Francisco, USA), was then injected through the pars plana into the vitreous cavity 3 to 4 mm posterior to the limbus, superotemporally. Triamcinolone acetonide (Triamhexal, Hexal AG, Holzkirchen, Germany), 0.05 ml (2 mg) was injected in the same manner using another syringe inferotemporally. The eye was then patched for 4 hours, topical chloramphenicol 0.5% was used every 6 hours thereafter for 3 days. All patients were examined 24 hours and 1 week after injection.

The primary outcome measures for efficacy were changes in BCVA and central macular thickness (CMT) by optical coherence tomography(OCT), 6 weeks after treatment. BCVA was measured at baseline and 6 weeks later using Snellen and ETDRS charts by a masked optometrist. CMT (central 1 mm) and central macular volume (central 3 mm) were measured using OCT (Stratus OCT, version 4.0.2; Stratus, Carl Zeiss Meditec, Dublin, CA, USA) at the same time intervals. Color fundus photography, assessment of autofluorescence and fluorescein angiography (FA) were performed in all patients at baseline and 6 weeks after intervention using the Heidelberg Retinal Angiograph II(HRA-II). Fundus autofluorescence was graded as follows: +1 for minimal changes [(Fig. 1)](#f1-jovr-3-95){ref-type="fig"}, +2 for moderate changes [(Fig. 2)](#f2-jovr-3-95){ref-type="fig"} and +3 for severe changes [(Fig. 3)](#f3-jovr-3-95){ref-type="fig"}. The CNV lesions were divided by size into small (\<4 DA) and large (≥4 DA). Fluorescein angiograms were reviewed by two masked authors (MRE and HA).

A minimum sample of 80 eyes (40 eyes in each study arm) was calculated to detect a 30% intergroup difference in CMT with study power of 0.8. Efficacy in the IVB and IVB/IVT groups was assumed to be 60% and 90% respectively. Data analysis was performed using t-test for comparing mean values between the two groups, and Chi-square or Fisher exact tests for comparing frequency values with significance level set at 0.05.

RESULTS
=======

A total of 106 eyes of 104 consecutive patients met the study criteria and were enrolled. Fourteen patients did not complete the 6-week follow-up. Eventually, data from 92 eyes of 90 patients with mean age of 70.6±8.7 (range 50--89) years, including 52 (57.7%) male and 38 (42.2%) female subjects were analyzed. Fiftythree and 39 eyes were allocated to the IVB and IVB/IVT groups respectively. Patients' demographics and ocular features at baseline were comparable between the study groups [(table 1)](#t1-jovr-3-95){ref-type="table"}.

Mean BCVA significantly improved from 1.03±0.40 to 0.93±0.38 logMAR (P=0.001) in the IVB group and from 1.08±0.33 to 0.91±0.38 logMAR (P=0.008) in the IVB/IVT group. Visual improvement was slightly greater in the IVB/IVT group (P=0.06). Overall, visual acuity improved 10 letters in 31 eyes (34%), 5--9 letters in 17 eyes (19%), remained unchanged in 32 eyes (35%) and decreased in 11 eyes (12%). The mean amount of decrease in visual acuity was 0.295 logMAR (approximately equivalent to 15 letters).

Mean CMT decreased from 361±115 to 248±115 μm (P\<0.001) in the IVB group and from 352±112 to 298±138 μm (P=0.008) in the IVB/IVT group. The difference between the two groups was not significant in this regard(P=0.38). Mean CMV decreased from 3.61 mm3 to 2.55 mm^3^ (P=0.001) in the IVB group and from 4.18 mm^3^ to 2.81 mm^3^ (P\<0.001) in the IVB/IVT group. The difference between the two groups was not significant (P=0.493).

Leakage on FA decreased in 27 (57.9%) eyes [(Fig. 4)](#f4-jovr-3-95){ref-type="fig"}, increased in 6 (12.8%) eyes and did not change in 14 (29.8%) eyes in the IVB group; corresponding figures in the IVB/IVT group were 21 (60%) eyes [(Fig. 5)](#f5-jovr-3-95){ref-type="fig"}, 2 (5.7%) eyes and 12 (34.3%) eyes, respectively. The difference between the two groups was not significant(P=0.556).

There was no difference between patients with lesions \<4 DA and ≥4 DA in terms of BCVA, 6 weeks after treatment (P=0.78). Improvement in visual acuity was more profound in eyes with minimal (+1) fundus autofluorescence at baseline as compared to eyes with +2(P=0.049) and +3 (P\<0.001) changes.

No significant change occurred in systolic(P=0.395) and diastolic (P=0.134) blood pressure after 6 weeks of follow-up. No patient developed uveitis, endophthalmitis, retinal toxicity or arterial thromboembolic events.

DISCUSSION
==========

The current study demonstrated that both IVB and IVB/IVT are well tolerated for treatment of neovascular AMD. There was no significant difference between the two modalities 6 weeks after treatment in terms of visual improvement, reduction of macular thickness and improved leakage on fluorescein angiography. Our results are consistent with previous studies reporting off-label IVB in patients with neovascular AMD.[@b16-jovr-3-95]--[@b32-jovr-3-95] This study indicates that the addition of 2 mg triamcinolone acetonide does not significantly enhance the efficacy of bevacizumab in patients with neovascular AMD at least in the short-term; however, there was a trend toward greater visual improvement in the IVB/IVT treated group. This lack of additive effect may reflect inadequate triamcinolone acetonide dosage, inadequate sample size, or short follow-up. Another explanation for lack of synergistic effect may be that bevacizumab and triamcinolone affect similar pathways in angiogenesis; therefore the additive effect may not be as significant as in the case of triamcinolone after PDT for neovascular AMD.[@b34-jovr-3-95]--[@b36-jovr-3-95]

Pegaptanib (Macugen) was the first anti- VEGF agent successfully used in the human eye. Although it was effective in preventing visual loss, visual improvement occurred in only 6% of patients one year after treatment.[@b6-jovr-3-95][@b38-jovr-3-95] In our study, visual gain of ≥10 letters and ≥5 letters was observed in 33% and 52.7% of the patients after 6 weeks.

Ranibizumab is an anti-VEGF antibody fragment recently developed for intraocular use. It is a small molecule that would theoretically penetrate the retina better than a fulllength antibody such as bevacizumab.[@b39-jovr-3-95] Using ranibizumab in patients with minimally classic and occult CNV, 25% of eyes treated with the 0.3 mg dosage and 33% of eyes treated with the 0.5 mg dosage had a 3-line improvement in visual acuity.[@b40-jovr-3-95] The short-term results of the mentioned studies are comparable to those of the current report. One drawback is that ranibizumab is more expensive and has a shorter half-life in the vitreous cavity necessitating repeat injections.[@b41-jovr-3-95]

Bevacizumab and ranibizumab have demonstrated similar efficacy in terms of visual improvement and stability; both agents provided stability of vision in 90 and 95% of eyes respectively. [@b41-jovr-3-95] In addition, both prevent severe visual loss (greater than 3 lines) in almost all patients. The rate of visual improvement of up to 2 lines, or from 3 to 5 lines, is also comparable. Three to five lines of visual improvement was observed in 38% of bevacizumab treated eyes and 30% of ranibizumab treated eyes.[@b27-jovr-3-95] It is noteworthy that bevacizumab outcomes are based on short-term data (3 months) whereas the visual improvement seen with ranibizumab has been shown to last for up to 2 years. Overall it seems quite possible that bevacizumab may be as effective as ranibizumab. The National Institute of Health is conducting a controlled study to compare bevacizumab and ranibizumab.[@b41-jovr-3-95]

We did not observe any instance of intraocular inflammation with bevacizumab in either study group which is in accordance with previous studies.[@b17-jovr-3-95]--[@b20-jovr-3-95] However, inflammation has been reported with ranibizumab[@b18-jovr-3-95] suggesting greater immunogenicity by the latter agent or existence of a proinflammatory component in the drug preparation. Ranibizumab is produced by bacteria but bevacizumab is produced using mammalian tissue culture[@b18-jovr-3-95], this may explain the lack of inflammatory reaction following bevacizumab injection.

We observed that patients with minimal(+1) fundus autofluorescence at baseline show better response to treatment. Under such circumstances, only minimal retinal pigment epithelial(RPE) cells are damaged and the prognosis for visual improvement is good. This noninvasive method may be used for prognostic purposes.

Follow-up period in this study was inadequate to make definite recommendations for treatment guidelines in neovascular AMD. Despite a trend toward better visual outcomes in the combined IVB/IVT group, triamcinolone acetonide did not have a clearly additive effect to bevacizumab in the treatment of neovascular AMD in terms of anatomical or functional outcomes. The study is being continued and longterm results will be published in near future.
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![Standard photograph 1: minimal fundus autofluorescence.](jovr-3-95f1){#f1-jovr-3-95}

![Standard photograph 2: moderate fundus autofluorescence.](jovr-3-95f2){#f2-jovr-3-95}

![Standard photograph 3: severe fundus autofluorescence.](jovr-3-95f3){#f3-jovr-3-95}

![Fluorescein angiography of the right eye of a patient in the intravitreal bevacizumab group; (A) early phase at baseline, (B) early phase 6 weeks after injection, (C) late phase at baseline and (D) late phase 6 weeks after injection.](jovr-3-95f4){#f4-jovr-3-95}

![Fluorescein angiography of the right eye of a patient in the intravitreal bevacizumab plus triamcinolone group; (A) early phase at baseline, (B) early phase 6 weeks after injection, (C) late phase at baseline, and (D) late phase 6 weeks after injection.](jovr-3-95f5){#f5-jovr-3-95}

###### 

Baseline and demographic characteristics of the study groups

  --------------------------------------------------------------
                             IVB\        IVB/IVT\    \*P value
                             group       group       
  -------------------------- ----------- ----------- -----------
  Age (years): M±SD          70.7±8.9    70.4±8.5    0.87

                                                     

  Smoking: No (%)                                    

  Yes                        12 (26.7)   13 (46.4)   

  No                         33 (73.3)   15 (53.6)   0.09

                                                     

  Size of lesion: No (%)                             

  \<4 DA                     27 (58.7)   23 (71.9)   

  ≥4 DA                      19 (41.3)   9 (28.1)    0.23

                                                     

  FA type: No (%)                                    

  Dominantly classic         22 (42.3)   17 (47.2)   

  Minimally classic          14 (26.9)   7 (19.4)    0.69

  Purely occult              12 (23.1)   9 (25.0)    

                                                     

  Autofluorescence: No (%)                           

  +1                         11 (28.2)   12 (35.3)   

  +2                         16 (41.0)   17 (50.0)   0.27

  +3                         12 (30.8)   5 (14.7)    

                                                     

  BCVA (logMAR): M±SD        1.03±0.40   1.08±0.33   0.72

                                                     

  CMT (μm): M±SD             361±115     352±112     0.66

                                                     

  CMV (mm^3^): M±SD          3.61±1.57   4.18±2.09   0.22

                                                     

  BP (mmHg): M±SD                                    

  Systolic                   129±24      120±28      0.23

  Diastolic                  76±12       75±11       0.79
  --------------------------------------------------------------

IVB, intravitreal bevacizumab; IVT, intravitreal triamcinolone; M, mean; SD, standard deviation; DA, disc area; FA, fluorescein angiography; BCVA, best-corrected visual acuity; CMT, central macular thickness; CMV, central macular volume; BP, blood pressure.

\*Chi-square for frequency values and t-test for mean values.
